Jennifer Whitty is an applied health economist with a professional background in pharmacy. She has considerable research leadership and consultancy experience in:

Jennifer’s research has a person-centred and multidisciplinary focus. She leads a program of research with a particular focus on evaluating patient and public preferences, choices and values around health outcomes and services. Her research contributes to the development of methods for measuring preferences and valuing quality of life and other outcomes from healthcare, and she is an expert in the application of choice-based stated preference approaches such as the discrete choice experiment. Jennifer is the leading health economics investigator for research projects funded by the Australian Research Council (ARC) and National Health and Medical Research Council (NHMRC), including the NHMRC Centre of Research Excellence in Telehealth. She has been awarded funding exceeding AU$9 million as a Chief Investigator or Fellow, approximately AU$10 million as Associate Investigator, and exceeding AU$8 million as a consultant on research grants. She has over 70 peer-reviewed journal publications and is a member of the Editorial Board for the international journals “Medical Decision Making” and “Applied Health Economics and Health Policy”. Jennifer has contributed to health policy development as a member of the National Immunoglobulin Governance Advisory Committee, which is a national advisory body in Australia supporting the effective and efficient governance of immunoglobulin products funded under the national blood arrangements.

Prior to her academic career, Jennifer has diverse experience working in the health system as a pharmacist, in both the United Kingdom and Australia. She has completed a Graduate Diploma in Clinical Pharmacy, and has promoted the quality use of medicines in clinical and policy settings. Jennifer’s research has retained a focus on the evaluation of health services, models of care, and health technologies including pharmaceuticals. She has worked closely with Government Health Departments and is an experienced evaluator of submissions made by pharmaceutical companies to have their products listed on the Australian Pharmaceutical Benefits Scheme (PBS).